Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

in patients with disease progression following treatment with a first-line, platinum-based chemotherapy doublet regimen.  

OGX-427 Clinical Development Highlights

  • In December 2012, the Company announced the initiation of the Pacific trial, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in approximately 80 men with CRPC who are experiencing a rising prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone acetate). The study is currently enrolling at sites in the United States and Canada.
  • The company-sponsored, randomized Phase 2 clinical trial of OGX-427 in combination with gemcitabine and cisplatin in patients with metastatic bladder cancer, Borealis-1, continues to enroll patients throughout the United States, Canada and Europe. The study aims to enroll approximately 180 patients and is expected to complete patient accrual in the second half of 2013.
  • The Company also recently announced plans for the initiation of an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in patients with advanced or metastatic bladder cancer who have disease progression following initial platinum-based chemotherapy.  The trial, Borealis-2, will seek to enroll approximately 200 patients to receive either OGX-427 plus docetaxel treatment or docetaxel treatment alone and is expected to begin in the first half of 2013.
  • Pacific, Borealis-1 and Borealis-2 are part of the "ORCA" (On-going studies evaluating treatment Resistance in CAncer) program that encompasses clinical studies of OGX-427 across multiple cancer indications. Plans to initiate additional studies as part of the ORCA program will be announced in the coming months.

    • Financial Update and Results

  • Revenue for the fourth quarter and year ended December 31, 2012 increased to
    '/>"/>

    • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... ANGELES , May 24, 2013  An international ... on Saturday, May 18, in Santa Monica, ... on new lung-sparing therapies for MPM, a rare form ... commonly affects the pleura, the lining of the chest. ... Lung and Blood Institute, the 3rd Annual International Symposium ...
    (Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
    (Date:5/24/2013)... The potential of the pulmonary ... therapeutic agents has been receiving undeniable attention with the ... promise. The crucial formulation considerations for orally inhaled products ... major role in the efficiency of pulmonary delivery, and ... new formulation techniques and devices in recent years. ...
    Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
    ... 9, 2008 Intra-Cellular Therapies, Inc.,today announced ... for ITI-007, the Company,s first-in-class dual 5HT2A ... low-dose formulation of ITI-007, which are in ... new data demonstrate,ITI-007 has preclinical activity both ...
    ... Kinase Inhibitor Phase 1 Trial in Advanced ... 2008 EntreMed, Inc.,(Nasdaq: ENMD ), ... treatment of cancer and inflammatory diseases, today,announced ... dose-escalation study for its,selective kinase inhibitor, ENMD-2076, ...
    Cached Medicine Technology:Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 2Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4
    (Date:5/24/2013)... May 24, 2013 CHI-California Healthcare ... and the California congressional delegation, joined by over ... industry user fees paid to the U.S. Food ... that future across-the-board cuts will not include user ... FY14 Agriculture, Rural Development and FDA Appropriations Bill. ...
    (Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Drugs commonly used ... side effects that can interfere with vision, according to ... analogues (PGAs), which are used to reduce eye pressure, ... and changes in eye color, the researchers said, suggesting ... for PGAs. Doctors should be conservative when ...
    (Date:5/24/2013)... (PRWEB) May 24, 2013 Let’s face it: ... is not uncommon for the majority of people to be ... is due to a coffee addiction or simply genetics, yellowish ... procedures are so popular. , Herald Square Dental ... very effective whitening system: Venus White Max. , Teeth ...
    (Date:5/24/2013)... 24, 2013 Area homeowners dreaming about owning ... hot tubs to choose from at factory-direct pricing during the ... sales event takes place at Emerald Pool and Patio ... , Jacuzzi, the industry's leading hot tub brand, scheduled the ... country. The event will feature popular hot tub models at ...
    (Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... Vinci lawsuit involving Intuitive Surgical Inc.’s da Vinci ... According to court records, a Washington State Court jury ... committed negligence in training a surgeon who performed a ... years later. The patient’s family had alleged in ...
    Breaking Medicine News(10 mins):Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3
    ... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,the ... ., Mr. Frank Massino, Senetek,s Chairman and ... greater visibility to Senetek at this,significant time in ...
    ... good models for human biology and disease. Now, ... that is transparent throughout its life. The new ... and observe processes like tumor metastasis and blood production ... fish, described in the February 7 issue of Cell ...
    ... Prescription pediatric drugs represent,an enormous market, with manufacturer sales ... forecast at a modest 3.2%, reaching $43,billion by 2011, ... 11.7%, is,expected to achieve the highest growth rate of ... new report The World Market for,Pediatric Drugs., The ...
    ... N.C., Feb. 6 With pharmaceutical sales,forces shrinking ... force will be a key driver in organizational ... structure conducive to motivating sales people,properly communicating goals ... both,organizational and personal goals., The Best Practice ...
    ... 6 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), ... been dosed in its Phase Ib, multi-center, open-label,ascending ... candidate,CD-NP, a novel chimeric natriuretic peptide, in development ... "We are very excited that dosing has begun ...
    ... to seek restatement of Beth Israel Deaconess,Medical Center audit, ... Douglas T. Linde should apply the same Sarbanes-Oxley,standards used ... role on the board of Beth Israel Deaconess Medical ... Workers East. Linde is,also the president and CFO of ...
    Cached Medicine News:Health News:Senetek PLC Announces Launch of New Website 2Health News:Transparent fish to make human biology clearer 2Health News:Transparent fish to make human biology clearer 3Health News:Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs 2Health News:Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 3Health News:Boston Properties Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: